Skip to main content
J

JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD. — Investor Relations & Filings

Ticker · 688488 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 928 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688488

About JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD.

Jiangsu Aidea Pharmaceutical Group Co., Ltd. is a biopharmaceutical enterprise focused on the research, development, manufacturing, and commercialization of innovative drugs. The company specializes in therapeutic areas with significant unmet medical needs, particularly anti-HIV treatments and anti-inflammatory medications. Its core product portfolio includes Ainuovirine (ACC007), a third-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1 infection, and Ainuomiti (ACC008), a single-tablet triple-combination regimen. Aidea Pharmaceutical maintains an integrated R&D platform and advanced manufacturing facilities to support its pipeline of small molecule drugs and biological products. The company aims to provide accessible and effective treatment solutions through continuous innovation in drug discovery and clinical development.

Recent filings

Filing Released Lang Actions
艾迪药业2025年年度股东会决议公告
Regulatory Filings
2026-04-20 Chinese
艾迪药业关于重大资产重组事项的进展公告
M&A Activity Classification · 1% confidence The document is a detailed progress announcement (“进展公告”) regarding a major asset reorganization transaction (acquisition of a 31.161% equity stake in Nanjing Nanda Pharmaceutical). It outlines the signing of equity purchase agreements, regulatory disclosures on the Shanghai Stock Exchange, installment payments, audit and legal opinions, and subsequent performance‐linked payments. This is clearly an ongoing M&A transaction update rather than an annual or interim report, earnings release, board change, or financing notice. Therefore, it fits the M&A Activity category.
2026-04-14 Chinese
国联民生证券承销保荐有限公司关于江苏艾迪药业集团股份有限公司重大资产购买之2025年度持续督导核查意见暨持续督导总结报告
M&A Activity Classification · 1% confidence The document is an independent financial advisor’s continuous supervision and summary report on a major asset purchase (重大资产购买) by Jiangsu Addi Pharmaceutical Group in 2025, including transaction structure, due diligence opinions, implementation status, and party commitments. It is not a regular annual or audit report but rather a disclosure relating to a major asset reorganization and purchase transaction, fitting the definition of M&A Activity (Code: TAR).
2026-04-14 Chinese
艾迪药业2025年年度股东会会议资料
Regulatory Filings
2026-04-10 Chinese
艾迪药业关于ACC085注射液获得药物临床试验批准通知书的自愿性披露公告
Regulatory Filings
2026-04-06 Chinese
公证天业会计师事务所（特殊普通合伙）关于江苏艾迪药业集团股份有限公司2025年度非经营性资金占用及其他关联资金往来情况的专项说明
Regulatory Filings
2026-03-30 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.